Lori Wirth, MD

home / authors / lori-wirth-md

Articles

OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

Lori Wirth, MD
May 12th 2022

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.

Facing Unmet Needs and Ongoing Trials in RR-DTC

Facing Unmet Needs and Ongoing Trials in RR-DTC

Lori Wirth, MD
April 20th 2022

Lori Wirth, MD, discusses the unmet needs and ongoing trials in development for patients with RR-DTC.

Treatment Options in RAI-refractory DTC in Second Line and Beyond

Treatment Options in RAI-refractory DTC in Second Line and Beyond

Lori Wirth, MD;Matthew Fowler
April 19th 2022

Lori Wirth, MD, discusses the role of cabozantinib in the second-line setting for patients with radioiodine-refractory differentiated thyroid cancer and reviews the results from the COSMIC-311 trial.

Frontline Treatment Options for RAI-refractory DTC

Frontline Treatment Options for RAI-refractory DTC

Lori Wirth, MD
April 8th 2022

Lori Wirth, MD, defines radioiodine-refractory differentiated thyroid cancer and discusses frontline treatment options for patients with the disease.

Presentation and Disease Course of Differentiated Thyroid Cancer

Presentation and Disease Course of Differentiated Thyroid Cancer

Lori Wirth, MD
March 30th 2022

Lori Wirth, MD, provides an overview of differentiated thyroid cancer including patient presentation and disease course.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Expanding Immunotherapy Use in Early-Stage Breast Cancer
Published: July 14th 2025 | Updated: July 25th 2025
Expanding Immunotherapy Use in Early-Stage Breast Cancer